TSC-202

N/A

Report date: 2025/05/07 14:45:43

Base Information

Drug NameTSC-202
Drug Alias NameTSC-202TSC-202-A0201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMelanoma-associated antigen 4 modulators
TargetsMelanoma-associated antigen 4
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsUrogenital Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTScan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTScan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsUrogenital Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A